NasdaqGS:UTHRBiotechs
United Therapeutics (UTHR) Could Be 17% Below Fair Value As First Quarter Miss Shakes Confidence
United Therapeutics (UTHR) is back in focus after reporting first quarter results with lower year-on-year revenue and a meaningful earnings miss versus analyst expectations, which weighed on investor confidence and pressured the stock.
See our latest analysis for United Therapeutics.
Beyond the weak first quarter, United Therapeutics’ share price has drifted, with a 30 day share price return of a 3.24% decline and a modest 3.28% gain over 90 days, while a 1 year total shareholder return of...